Ciprofloxacin criteria in antimicrobial prophylaxis and bladder cancer recurrence

Medical Science Monitor

Volumn 16, Issue 10, 2010, Pages

  Gurtowska, Natalia ^a   Kloskowski, Tomasz ^a   Drewa, Tomasz ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Chair and Department of General Oncologic and Pediatric Urology   (Poland)

Author keywords

Bladder cancer; Ciprofloxacin; Treatment

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING); MITOCHONDRIAL DNA; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIRUBICIN;

ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; CANCER CELL CULTURE; CANCER RECURRENCE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CYTOTOXICITY; EUKARYOTIC CELL; HUMAN; REVIEW; BLADDER TUMOR; DOSE RESPONSE; DRUG COMBINATION; DRUG SCREENING; PATHOLOGY; TRANSITIONAL CELL CARCINOMA; TUMOR CELL LINE; TUMOR RECURRENCE; CANCER INHIBITION; CELL CYCLE PROGRESSION; DNA DAMAGE; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY, COMBINATION; EPIRUBICIN; HUMANS; NEOPLASM RECURRENCE, LOCAL; URINARY BLADDER NEOPLASMS;

EID: 77958147019     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet, 2009; 374: 239-249
2. Halachmi S, Madeb R, Kravtsov A et al: Bladder cancer - genetic overview. Med Sci Monit, 2001; 7(1): RA164-RA168
3. Kaufman DS: Challenges in the treatment of bladder cancer. Ann Oncol, 2006; 17 (Suppl.5): 106-112
4. Seay TM, Peretsman SJ, Dixon PS: Inhibition of human transitional cell carcinoma in vitro cell proliferation by fluoroquinolone antibiotics. J Urol, 1996; 155: 757-762
5. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol, 1995, 153: 1444-1450
6. Hudson MA: When intravesical measures fail: indications for cystectomy in superficial disease. Urol Clin North Am, 1992, 19: 601
7. Witjes JA, Hendricksen K: Intravesical pharmacotherapy for non-muscleinvasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol, 2008; 53: 45-52
8. Kamat AM, Lamm DL: Antitumor activity of common antibiotics against superficial bladder cancer. Urology, 2004; 63: 457-460
9. Yamashita Y, Ashiwaza T, Morimoto M et al: Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Research, 1992; 52: 2818-2822
10. Elsea SH, McGuirk PR, Gootz TD et al: Drug features that contribute to the activity of quinolones against mammalian topoisomerases ii and cultured cells: Correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother, 1993; 37: 2179-2186
11. Hussy P, Maass G, Tummler B et al: Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. Antimicrob Agents Chemother, 1986; 29: 1073-1078
12. Miclau T, Edin ML, Lester GE et al: Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res, 1998; 16: 509-512
13. Aranha O, Grignon R, Fernandes N et al: Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol, 2003; 22: 787-794
14. Aranha O, Wood DP Jr, Sarkar FH: Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res, 2000; 6: 891-900
15. Somekh E, Douer D, Shaked N, Rubinstein E: In vitro effects of ciprofloxacin and pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther, 1989; 248: 415-418
16. Herold C, Ocker M, Ganslmayer M et al: Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer, 2002; 86: 443-448
17. Mondal ER, Das SK, Mukherjee P: Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac J Cancer Prev, 2004; 5: 196-204
18. Herbold BA, Brendler-Schwaab SY, Jurgen H: Ciprofloxacin: in vivo genotoxicity studies. Mutat Res, 2001; 498: 193-205
19. Smart DJ: Genotoxicity of topoisomerase II inhibitors: An anti-infective prospective, Toxicology, 2008; 254: 192-198
20. Elsea SH, Westergaard M, Burden DA et al: Quinolones share a common interaction domain on topoisomerase II with other DNA cleavageenhancing antineoplastic drugs. Biochemistry, 1997; 36: 2919-2914
21. Giles GI, Sharma RP: Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med Chem, 2005; 1: 383-394
22. Smart DJ, Halicka HD, Traganos F et al: Ciprofloxacin-induced G2 arrest and apoptosis in TK6 lymphoblastoid cells is not dependent on DNA double-strand break formation. Cancer Biol Ther, 2008; 7: 113-119
23. Holtom PD, Pavkovic SA, Bravos PD et al: Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J Orthop Res, 2000; 18: 721-727
24. Lawrence JW, Darkin-Rattray SJ, Xie F et al: 4-Quinolones cause a selective loss of mitochondrial DNA from mouse L1210 leukemia cells. J Cell Biochem, 1993; 51: 165-174
25. Lawrence JW, Claire DC, Weissig V, Rowe TC: Delayed cytotoxicity and cleavage of mitochondrial DNA in Ciprofloxacin-treated mammalian cells. Mol Pharmacol, 1996; 50: 1178-1188
26. Kozieł R, Zabłocki K, Duszyński J: Calcium signals are affected by ciprofloxacin as a consequence of reduction of mitochondria DNA content in Jurkat cells. Antimicrob Agents Chemother, 2006; 50: 1664-1671
27. Hayem G, Petit PX, Levacher M et al: Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial resistance. Antimicrob Agents Chemother, 1994; 38: 243-247
28. Aqrawal N, Ray RS, Farooq M et al: Photosensitizing potential of ciprofloxacin at ambient level of UV radiation. Photochem Photobiol, 2007; 83: 1226-1236
29. Wagai N, Tawara K: Possible direct role of reactive oxygens in the cause of cutaneous phototoxicity induced by five quinolones in mice. Arch Toxicol, 1992; 66: 392-397
30. Gurbay A, Hincal F: Ciprofloxacin-induced glutathione redox status alterations in rat tissues. Drug Chem Toxicol, 2004; 27: 233-242
31. Gurbay A, Garrel C, Osman M et al: Cytotoxicity in ciprofloxacin-treated human fibroblast cells and protection by vitamin E. Hum Exp Toxicol, 2002; 21: 635-641
32. Jun YT, Kim HJ, Song MJ et al: In vitro effects of ciprofloxacin and roxithromycin on apoptosis of Jurkat T lymphocytes. Antimicrob Agents Chemother, 2003; 47: 1161-1164
33. Pinto AC, Moreira JN, Simoes S: Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol, 2009; 64(3): 445-454. Epub 2008 Dec 23
34. El-Rayes BF, Grignon R, Aslam N et al: Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells. Int J Oncol, 2002; 21: 207-211
35. Mukherjee P, Das SK: Action of retinoic acid on human glioblastomaastrocytoma-14 cells in culture. Neoplasma, 1995; 42: 123-128
36. Eriksson E, Forsgren A, Reisbeck K: Several gene programs are induced in ciprofloxacin-treated human lymphocytes as revealed by microarray analysis. J Leukoc Biol, 2003; 74: 456-462
37. Lettieri JT, Rogge MC, Kaiser L et al: Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother, 1992; 36: 993-996
38. Brunner M, Stabeta H, Möller JG, Schrolnberger BD et al: Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother, 2002; 46: 3724-3730
39. Hakim A, Kallel H, Sahnoun Z et al: Lack of nephrotoxicity following 15-day therapy with high doses of colistin in rats. Med Sci Monit, 2008; 14(4): BR74-77
40. Falagas M, Polemis M, Alexiou V et al: Antimicrobial resistance of Escherichia coli urinary isolates from primary care patients in Greece. Med Sci Monit, 2008, 14(2): CR75-79
41. Yilmaz N, Agus N, Gul Yurtsever S et al: Prevalence and antimicrobial susceptibility of Escherichia coli in outpatient urinary isolates in Izmir, Turkey. Med Sci Monit, 2009; 15(11): PI61-65
42. Ebisuno S, Inagaki T, Kohijmoto Y, Ohkawa T: The cytotoxic effects of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro. Cancer, 1997; 80: 2263-2267
43. Arnha O, Zhu L, Alhasan S et al: Role of mitochondria in ciprofloxacin induced apoptosis in bladder cancer cells. J Urol, 2002; 167: 1288-1294
44. Kamat AM, DeHaven JI, Lamm DL: Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology, 1999; 54: 56-61
45. Gruber B, Bubko I, Krzyszton-Russjan J, Anuszewska E: Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms. Med Sci Monit, 2010; 16(1): BR45-51
46. Engeler DS, Scandella E, Schmid HP, Ludewig B: Epirubicin and ciprofloxacin synergistically induce apoptosis in human urothelial cancer cell lines. Urology, 2007; 70(Suppl.3A): 62
47. http: //clinicaltrials.gov/ct2/show/NCT00003824?term=ciprofloxacin&rank=42